Daniel P Cardinali, Gregory M Brown, Seithikurippu R Pandi-Perumal
7 min
As populations age, the prevalence of circadian rhythm disruption and persistent sleep issues—often linked to "inflammaging"—increases, raising the risk for metabolic, cardiovascular, and neurodegenerative diseases. This review examines the physiological role of melatonin in healthy aging, evaluates its efficacy as a therapeutic intervention for sleep disorders, and assesses its safety profile for elderly populations.
The authors synthesize physiological, clinical, and epidemiological evidence regarding the role of melatonin as an endogenous chronobiotic. They analyze how age-related declines in pineal melatonin production correlate with sleep fragmentation and the loss of circadian synchronization. Furthermore, the paper reviews clinical trial data concerning melatonin's use in insomnia, benzodiazepine withdrawal, and its potential neuroprotective roles in conditions like Alzheimer’s and Parkinson’s disease.
Melatonin serves two primary functions: acting as a "signal of darkness" that synchronizes the central circadian pacemaker in the suprachiasmatic nuclei, and acting as a powerful antioxidant and anti-inflammatory agent. The review highlights that melatonin can significantly improve sleep efficiency and phase-shifting in the elderly. Beyond sleep, the authors propose that melatonin’s role in glymphatic system function—which is critical for brain waste clearance—may provide a neuroprotective buffer against cognitive decline. Finally, the authors emphasize that while short-term usage of melatonin is consistently shown to be safe, there is an urgent need for more standardized pharmaceutical formulations, as over-the-counter preparations often contain inconsistent dosages and contaminants.
This paper provides a clinical perspective on why sleep quality is not just a comfort issue, but a critical component of healthy aging. By positioning melatonin as both a chronobiotic and an anti-inflammatory tool, the authors offer a rationale for its wider use in geriatric care. However, they caution against the "cure-all" mythos surrounding the hormone, advocating for ethical, evidence-based prescribing rather than the unregulated self-supplementation currently prevalent in the market.
Alex: Its contribution is an integrated argument, not a newly discovered effect. The authors connect disrupted rhythms with inflammaging, meaning persistent low-grade inflammation associated with aging. They argue that melatonin deserves attention because it combines timing effects with anti-inflammatory and cell-protective actions.
Sam: A molecule can have several biological actions without delivering several clinical benefits. Where does the review make the sleep claim concrete?
Alex: One example is a crossover study involving twenty-four healthy older adults. It compared placebo with different melatonin doses. The higher dose, five milligrams before bed, improved sleep efficiency: the share of time in bed actually spent asleep.
Sam: Was that more deep sleep, or just more sleep overall? Those would support different interpretations.
Alex: The reported improvement came mainly from more time in a lighter stage of non-dreaming sleep, with somewhat fewer awakenings. The excerpt gives no numerical size for the improvement. So we can describe the direction, but not tell listeners how many extra minutes they should expect.
Sam: And these were healthy older adults, not people selected for severe insomnia or dementia. I’d treat that as a useful demonstration, not a universal treatment result.
Alex: That’s the appropriate scope for this example. The review also draws on broader clinical literature, but its conclusion explicitly says melatonin is not for every sleep disorder. Its strongest organizing case concerns disrupted timing, rather than all causes of poor sleep.
Sam: Where does brain disease enter? The review seems to connect sleep quality with more than next-day tiredness.
Alex: It discusses the glymphatic system, a fluid-exchange process involved in clearing waste from the brain. That exchange occurs primarily during non-dreaming sleep. The authors connect impaired clearance and disturbed sleep with questions about neurodegeneration, while acknowledging that sleep-deprivation findings do not establish Alzheimer’s disease causation.
Sam: That gives a plausible pathway, but not evidence that taking melatonin prevents dementia. What clinical evidence does the review actually describe?
Alex: It cites analyses reporting improved sleep in people with mild cognitive impairment: measurable cognitive difficulties with daily functioning still preserved. It also describes retrospective patient studies reporting better cognitive and emotional outcomes among melatonin users. Those comparisons cannot, by themselves, establish that melatonin caused the improvements.
Sam: And if low melatonin accompanies cognitive decline, it could be a consequence rather than a cause.
Alex: The authors explicitly say that direction remains unknown. They also discuss possible protection in Parkinson’s-related conditions, including a single-patient report. For me, that makes the section a map of hypotheses and early clinical signals, not proof that melatonin prevents progressive brain disease.
Sam: There’s another practical comparison here: conventional sleeping medicines. Does the review show melatonin can replace them?
Alex: It discusses benzodiazepines and related sleep medicines, which can have less predictable effects in older adults. It also considers melatonin during withdrawal from those drugs. But the studies and reviews disagree, so this is not a settled replacement strategy.
Sam: Let’s turn to safety. The review describes melatonin as generally well tolerated, but that phrase can conceal both side effects and missing follow-up.
Alex: One safety review covered thirty-seven randomized, placebo-controlled trials of sleep disturbances. Daytime drowsiness was the most frequently reported adverse effect, affecting roughly two percent of participants. Severe or clinically significant events were very uncommon, but the review stressed the lack of long-term randomized data.
Sam: So reassuring trial results don’t establish that taking it indefinitely is harmless. What other qualifications should researchers keep in view?
Alex: Higher-dose trials suggested more sleepiness, headache, and dizziness, despite no clear increase in serious adverse events in the strongest subset. The authors also flag possible drug interactions and differences between individuals. Dose and timing can matter for unwanted effects as well as benefits.
Sam: There’s also a difference between the molecule studied and the product someone buys. Does the review address that?
Alex: It does. The authors report concerns about inconsistent doses, impurities, and variable bioavailability in unlicensed preparations. That matters because a favorable safety profile for melatonin does not settle the quality of every formulation. They also distinguish low-dose timing effects from broader cellular effects that may require substantially higher doses.
Sam: So who should read the full review, and where would you send them first?
Alex: Researchers in sleep, aging, or neurodegeneration should start with “Melatonin and Sleep,” then “Safety for the Clinical Use of Melatonin.” Read the neurodegenerative-disorders section with study design in mind: sleep improvement, retrospective cognitive findings, and disease-prevention hypotheses carry different evidential weight. For everyone else: better sleep is a benefit, not proof of disease prevention.
Sam: Keep that distinction in mind.